Research programme: ASK1 inhibitors - Seal Rock Therapeutics
Latest Information Update: 28 Dec 2022
At a glance
- Originator Seal Rock Therapeutics
- Class Hepatoprotectants; Small molecules
- Mechanism of Action MAP-kinase-activated kinase 5 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Non-alcoholic steatohepatitis
Most Recent Events
- 28 Dec 2022 No recent reports of development identified for preclinical development in Non-alcoholic-steatohepatitis in USA
- 09 Nov 2018 Preclinical trials in Non-alcoholic steatohepatitis in USA (unspecified route)